Premium
Bromocriptine, Methyl Testosterone and Placebo for Inhibition of Physiological Lactation: A Controlled Study
Author(s) -
Biggs J. S. G.,
Hacker N.,
Andrews E.,
Munro C.
Publication year - 1978
Publication title -
medical journal of australia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 131
eISSN - 1326-5377
pISSN - 0025-729X
DOI - 10.5694/j.1326-5377.1978.tb77383.x
Subject(s) - prolactin , bromocriptine , lactation , endocrinology , medicine , placebo , testosterone (patch) , mammary gland , breast milk , hormone , chemistry , biology , pregnancy , breast cancer , biochemistry , alternative medicine , pathology , cancer , genetics
Lactation occurs when the fully developed breast is released from the inhibitory influence which oestrogen and progesterone exert upon the action of prolactin. The use of oestrogens to suppress lactation depends on a continuation of the peripheral, that is, mammary, inhibition of prolactin. Androgens are also believed to act by inhibition of the action of prolactin on the mammary gland epithelium. Bromocriptine, when compared in a double–blind trial with orally administered methyl testosterone and placebo, gave almost complete relief of breast discomfort and congestion, though a small amount of milk production was seen. Methyl testosterone, in the dosage used in this study, was quite ineffective in suppressing lactation or breast symptoms.